Replies to post #207494 on Biotech Values

[DewDiligence]

TCON’s new slide deck—with 12/31/16 cash balance:

https://www.sec.gov/Archives/edgar/data/1394319/000156459017000168/tcon-ex991_6.htm

At 12/31/16, TCON had $44.4M in cash, $8.0M in debt, and 16.1M basic shares outstanding.

[DewDiligence]

TCON doses first phase-3 patient in angiosarcoma:

http://finance.yahoo.com/news/tracon-pharmaceuticals-announces-first-patient-130000400.html